A phase II study of MGCD0103 (MG-0103) in patients with refractory chronic lymphocytic leukemia
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2015
At a glance
- Drugs Mocetinostat (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Celgene Corporation; MethylGene; Pharmion Corporation
- 12 May 2009 Additional lead trial investigator Martell R identified as reported by ClinicalTrials.gov.
- 16 Dec 2008 Status changed from suspended to completed, according to clinicaltrials.gov.
- 22 Sep 2008 Planned end date changed to 1 Jun 2009, as reported by ClinicalTrials.gov.